
Pall T Onundarson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4953709/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity scoreâ€weighted study. Journal of Internal Medicine, 2022, , .	6.0	2
2	Platelet function testing: Current practice among clinical centres in Northern Europe. Haemophilia, 2022, 28, 642-648.	2.1	5
3	Genetic architecture of band neutrophil fraction in Iceland. Communications Biology, 2022, 5, .	4.4	1
4	A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over sevenâ€day storage. Transfusion, 2021, 61, 202-211.	1.6	2
5	A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. Communications Biology, 2021, 4, 156.	4.4	72
6	lgnoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study. Blood, 2021, 137, 2745-2755.	1.4	6
7	Genetic variants associated with platelet count are predictive of human disease and physiological markers. Communications Biology, 2021, 4, 1132.	4.4	7
8	Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants. Annals of Internal Medicine, 2021, 174, 1493-1502.	3.9	47
9	Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article. Thrombosis Journal, 2021, 19, 72.	2.1	2
10	FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. Nature, 2020, 584, 619-623.	27.8	81
11	Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis. Nature Communications, 2020, 11, 393.	12.8	59
12	Predicted loss and gain of function mutations in ACO1 are associated with erythropoiesis. Communications Biology, 2020, 3, 189.	4.4	30
13	The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin. Journal of Thrombosis and Thrombolysis, 2019, 48, 685-689.	2.1	2
14	Oral anticoagulant monitoring: Are we on the right track?. International Journal of Laboratory Hematology, 2019, 41, 40-48.	1.3	5
15	A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. Nature Genetics, 2019, 51, 267-276.	21.4	83
16	Sequence variants associating with urinary biomarkers. Human Molecular Genetics, 2019, 28, 1199-1211.	2.9	28
17	A truncating mutation in EPOR leads to hypo-responsiveness to erythropoietin with normal haemoglobin. Communications Biology, 2018, 1, 49.	4.4	9
18	Replacing PT-INR Monitoring of Warfarin with Fiix-NR in Clinical Practice Reduces Thromboembolism without Increasing Bleeding Despite Reduced Number of Dose Adjustments. Blood, 2018, 132, 1239-1239.	1.4	1

PALL T ONUNDARSON

#	Article	IF	CITATIONS
19	During warfarin induction, the Fiixâ€prothrombin time reflects the anticoagulation level better than the standard prothrombin time. Journal of Thrombosis and Haemostasis, 2017, 15, 131-139.	3.8	6
20	Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial. Journal of Thrombosis and Thrombolysis, 2017, 43, 550-561.	2.1	7
21	A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma. Journal of Thrombosis and Haemostasis, 2016, 14, 1043-1053.	3.8	11
22	Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. Lancet Haematology,the, 2015, 2, e231-e240.	4.6	23
23	Clinical phenotype in heterozygote and biallelic <scp>B</scp> ernardâ€ <scp>S</scp> oulier syndrome—A case control study. American Journal of Hematology, 2015, 90, 149-155.	4.1	29
24	Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial. Blood, 2015, 126, 1134-1134.	1.4	0
25	Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial. Blood, 2015, 126, 1129-1129.	1.4	0
26	Complementary effect of fibrinogen and rFVIIa on clotting <i>ex vivo</i> in Bernard-Soulier syndrome and combined use during three deliveries. Platelets, 2014, 25, 357-362.	2.3	8
27	Apolipoprotein(a) Genetic Sequence Variants Associated With Systemic Atherosclerosis and Coronary Atherosclerotic Burden But Not With Venous Thromboembolism. Journal of the American College of Cardiology, 2012, 60, 722-729.	2.8	149
28	Seventy-five genetic loci influencing the human red blood cell. Nature, 2012, 492, 369-375.	27.8	320
29	Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time. Thrombosis Research, 2012, 130, 674-681.	1.7	19
30	Screening for anemia in patients on warfarin facilitates diagnosis of gastrointestinal malignancies and pre-malignant lesions. Thrombosis Research, 2012, 130, e20-e25.	1.7	14
31	Recombinant factor <scp>VIIa</scp> as lastâ€resort treatment of desperate haemorrhage. Acta Anaesthesiologica Scandinavica, 2012, 56, 636-644.	1.6	14
32	Nordic Haemophilia Council's Practical Guidelines on Diagnosis and Management ofvon Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2011, 37, 495-502.	2.7	24
33	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nature Genetics, 2010, 42, 692-697.	21.4	181
34	A â€~pilot' study on airâ€ŧravel and venous thromboembolism. British Journal of Haematology, 2009, 146, 457-459.	2.5	2
35	Quantification of menstrual flow by weighing protective pads in women with normal, decreased or increased menstruation. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 275-279.	2.8	12
36	The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery. Thrombosis Research, 2009, 124, 695-700.	1.7	19

PALL T ONUNDARSON

#	Article	IF	CITATIONS
37	On the significance of marginally low von Willebrand factor. Thrombosis and Haemostasis, 2008, 100, 1213-4.	3.4	0
38	Economy Class Syndrome: A "Pilot―Study Blood, 2005, 106, 4130-4130.	1.4	0
39	Mesenteric Panniculitis Presenting with Autoimmune Haemolytic Anaemia. Acta Haematologica, 2002, 107, 35-37.	1.4	7
40	Progressive multifocal leukoencephalopathy after fludarabine therapy for lowâ€grade lymphoproliferative disease. American Journal of Hematology, 2002, 70, 51-54.	4.1	50
41	Epidemiology of hairy cell leukemia in Iceland. The Hematology Journal, 2002, 3, 145-147.	1.4	11
42	Recombinant Factor VIIa for Bleeding in Refractory Thrombocytopenia. Thrombosis and Haemostasis, 2000, 83, 634-635.	3.4	95
43	Performance of Prothrombin-Proconvertin Time as a Monitoring Test of Oral Anticoagulation Therapy. American Journal of Clinical Pathology, 1997, 107, 672-680.	0.7	8
44	Low-dose cytosine arabinoside as remission induction therapy in refractory adult acute lymphocytic leukemia. American Journal of Medicine, 1989, 86, 493-494.	1.5	4